Smith Mark Douglas Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$28,312.00
Insider Sells Quantity
9
Insider Sells Sum
$1.59M

Insider Activity of Smith Mark Douglas

According to the SEC Form 4 filings, Smith Mark Douglas, being in a position of

  1. director at Jazz Pharmaceuticals plc,
    оver the last 12 months, has bought 0 shares, and sold 1157 shares for $266,746,
    over all time since 2021-12-02, has bought 0 shares, and sold 4741 share for $769,363.

Biography of Smith Mark Douglas

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $266,7461100

Comparison of Insiders on Amount of Buys and Sells

2026-06-15SaleJazz Pharmaceuticals plc
JAZZ
director
1,157
0.0018%
$230.55$266,746+4.58%
2025-07-02SalePhreesia, Inc.
PHR
director
7,000
0.0117%
$29.00$203,000-43.36%
2024-08-15PurchaseTeladoc Health, Inc.
TDOC
director
4,000
0.0024%
$7.08$28,312+21.67%
2024-07-18SalePhreesia, Inc.
PHR
director
7,000
0.0135%
$25.00$175,000+9.69%
2023-12-04SaleJazz Pharmaceuticals plc
JAZZ
director
417
0.0007%
$119.27$49,736-6.84%
2023-08-14SaleJazz Pharmaceuticals plc
JAZZ
director
1,241
0.0019%
$138.16$171,454-13.99%
2023-04-03SalePhreesia, Inc.
PHR
director
7,000
0.0133%
$30.77$215,367-17.09%
2022-12-02SaleJazz Pharmaceuticals plc
JAZZ
director
420
0.0007%
$154.68$64,966-13.69%
2022-08-05SaleJazz Pharmaceuticals plc
JAZZ
1,089
0.0017%
$152.32$165,879-6.53%
2021-12-02SaleJazz Pharmaceuticals plc
JAZZ
director
417
0.0007%
$121.30$50,582+21.6%
2021-01-04SalePhreesia, Inc.
PHR
director
12,000
0.0206%
$40.27$483,197+16.32%
2020-08-10SalePhreesia, Inc.
PHR
director
12,000
0.0178%
$17.51$210,085+72.03%
Total: 12
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.